Product Code: RP-ID-10082369 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10082369
Market Overview:
Mesenchymal Stem Cell (MSC) Market Segmentation by Treatment Type (Autologous and Allogeneic); by Product & Service (Cell Sourcing, Culture & Cryopreservation, and Others); by Source of Isolation (Bone Marrow, Cord Blood, Peripheral Blood, Lungs, and Others); by Application (Disease Modelling, Oncology Disorders, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, and Others); by Stem Cells Indication (Cardiovascular Disease, Liver Disease, Cancer, and Others)-Global Demand Analysis & Opportunity Outlook 2031
Global Mesenchymal Stem Cell (MSC) Market Highlights Over 2022 - 2031
The global mesenchymal stem cell (MSC) market generated revenue of around USD 3 billion in the year of 2021 and is estimated to grow at a CAGR of ~14% over the forecast period, i.e., 2022 - 2031. The growth of the market can be attributed to the increase in the aging population who are prone to different types of diseases, and to the rising use of mesenchymal stem cells as a substitute surgery for knee replacement and other operative procedures. According to the United Nations, the global share of population of age 65 or over increased from 6% in 1990 to 9% in 2019.
CLICK TO DOWNLOAD SAMPLE REPORT
Mesenchymal stem cells are adult stem cells. These cells can be differentiated into many different types of cells within the body, such as bone cells, cartilage, muscle cells, neural cells, skin cells, and corneal cells. MSC has high potential for tissue repair. In addition, these cells are isolated from other tissues like fallopian tube, fetal liver, peripheral blood, and fetal lung among others. MSC cells can supplement a person’s stem cell count through transplantation with highly competent cells. Moreover, MSCs are also known to be a renewable source to replace tissues and cells for the treatment of disabilities and diseases.
The covid-19 pandemic began in late 2019 and is persisting as a dangerous threat to mankind. However, as discovered by the heroes of medical science, the advent of MSC has achieved a promising result for the stem cell therapy of covid-19. As given, MSCs are known for their potential for immunomodulation, defense against infection caused by viruses, and tissue regeneration. Although the dynamics of the market in multiple fields have been affected poorly, the mesenchymal stem cell market has rather gained more recognition during the pandemic.
The global mesenchymal stem cell market is segmented by treatment type, product & service, source of isolation, application, and stem cell indication. Based on application, the market is segmented into disease modelling, oncology disorders, drug development & discovery, stem cell banking, tissue engineering, and others. Among these segments, the oncology disorder segment is anticipated to hold the largest share in the market by the end of 2031 and is expected to grow at the highest CAGR during the forecast period. This rise in the growth of the segment is a result of increasing cancer cases, wherein the branch of oncology deals with the prevention, treatment, and diagnosis of cancer.
Global Mesenchymal Stem Cell (MSC) Market Regional Synopsis
Regionally, the global mesenchymal stem cell market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the North America region witnessed noteworthy growth in the global market for mesenchymal stem cells (MSC) in the year 2021 as a result of large number of aging population and increasing incidence of cancers. Alternatively, the market in the Asia Pacific region is expected to grow with the highest CAGR during the forecast period. China and India are estimated to be the fastest-growing MSC markets in the region. The growth of MSC market in these regions can be attributed to the increasing number of aging patients and government initiative such as check-up camps, sufficient funding to the healthcare sector, and many more for aiding the growth of the market. As sourced from United Nations, the population having the age of 65 and over accounted to 395,344 thousand in the year 2019 and is predicted to reach 587,415 thousand by the end of the year 2030 in the Asia Pacific region.
Market Segmentation
Our in-depth analysis of the global mesenchymal stem cell market includes the following segments:
By Treatment Type
-
Autologous
-
Allogeneic
By Product & Service
-
Cell Sourcing
-
Culture & Cryopreservation
-
Others
By Source of Isolation
-
Bone Marrow
-
Cord Blood
-
Peripheral Blood
-
Lungs
-
Others
By Application
-
Disease Modelling
-
Oncology Disorders
-
Drug Development & Discovery
-
Stem Cell Banking
-
Tissue Engineering
-
Others
By Stem Cells Indication
-
Cardiovascular Disease
-
Liver Disease
-
Cancer
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Mesenchymal Stem Cell Market
Growth Drivers
-
Increasing incidence of chronic diseases
-
Increasing investments in stem cell research
Challenges
-
Lack of therapeutic advancement related to stem cell
Key Companies Dominating the Global Mesenchymal Stem Cell (MSC) Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global mesenchymal stem cell (MSC) market that are included in our report are Cell Applications, Inc., Celprogen Inc., STEMCELL Technologies Inc., Axol Bioscience Ltd., Cytori Therapeutics Inc., Proteona Pte. Ltd., BrainStorm Cell Limited, Stemedica Cell Technologies, Inc., Mesoblast Ltd., ScienCell Research Laboratories, Inc., Neuromics, and others.
Latest Developments in the Global Mesenchymal Stem Cell Market:
-
1 September 2021: STEMCELL Technologies partnered with WiCell in order to launch human pluripotent stem cell (hPSC), to help researchers in achieving critical analysis of cell characterization through comprehensive cell quality assessments.
- 19 November 2020: Novartis announced a collaboration agreement with Mesoblast in order to develop and manufacture “remestemcel-L” with the agenda of treating acute respiratory distress syndrome (ARDS).
Key Reasons to Buy Our Report
-
The report covers a detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessments for overall growth.
-
We provide customized reports as per the clients’ requirements helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goals.
- Cell ApplicationsInc.
- Celprogen Inc.
- STEMCELL Technologies Inc.
- Axol Bioscience Ltd.
- Cytori Therapeutics Inc.
- Proteona Pte. Ltd.
- BrainStorm Cell Limited
- Stemedica Cell Technologies Inc.
- Mesoblast Ltd.
- ScienCell Research LaboratoriesInc.
- Neuromics
Related Reports
Proof of Quality & Reliability
